Cancer Therapy Nephrotoxicity: Match Drug to Renal Pattern

Student Handouts and Nephrology Primer · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Name the drug, identify the renal pattern, and target prevention and monitoring to that mechanism.

Different therapies injure different structures. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

Different therapies injure different structures. Vessels / glomerulus — VEGF inhibition: BP and protein clues; Proximal tubule — Cisplatin toxicity; ifosfamide transport loss; Tubular lumen — Methotrexate precipitation / delayed elimination; Interstitium — Also assess competing drug and illness causes. Separate direct injury from drug accumulation; the response must preserve cancer and kidney goals. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

Cisplatin: tubules and electrolytes

Look for AKI and magnesium wasting; follow creatinine, magnesium, potassium, and volume status. Use the oncology regimen’s hydration and electrolyte protocol and review additional nephrotoxins.

Ifosfamide: proximal transport

Normoglycemic glycosuria, phosphate loss, bicarbonate wasting, and tubular proteinuria suggest Fanconi-type injury. A stable creatinine does not exclude clinically important proximal dysfunction.

Methotrexate: delayed elimination

High-dose therapy requires protocolized hydration, urine alkalinization, drug-level monitoring, and rescue. Rising creatinine with delayed clearance is an urgent oncology/pharmacy problem; routine outpatient advice is inadequate.

VEGF pathway: BP and protein

New hypertension, proteinuria, or thrombotic microangiopathy features suggest endothelial/glomerular injury. Measure urine protein and BP, assess hemolysis when indicated, and coordinate drug decisions with oncology and nephrology.

Separate therapy toxicity from other AKI

Check sepsis, dehydration, obstruction, tumor lysis, and other drugs. A temporal association helps generate a hypothesis but does not establish that chemotherapy caused every creatinine rise.

Worked comparison

Magnesium loss after cisplatin suggests a tubular problem. Marked proteinuria and hypertension on VEGF inhibition suggests a glomerular/endothelial problem. The second pattern needs more than electrolyte replacement.

Continue learning